Welcome Dr. Sokolov to our Advisory Board & Investment Committee!
We are thrilled to welcome Dr. Jacque Sokolov to our Advisory Board and Investment Committee!
Dr. Sokolov’s deep expertise in clinical medicine, investment strategy, and healthcare innovation is uniquely aligned with Seed Healthcare’s mission to advance early disease detection and support disruptive technologies that transform preventative care. His proven ability to guide healthcare companies through critical strategies makes him an invaluable addition to both our Advisory Board and Investment Committee.
Our President & CEO, Todd Perman, recently sat down with Dr. Sokolov to discuss his career, impact, and vision for joining Seed Healthcare.
You’ve had a very impressive career from pioneering multiple “Physician Practice Management (PPM)” companies to leading healthcare technology innovation in mRNA, DNA, Digital Health and AI enabled clinical solutions and finally, serving in many governmental advisory roles. How do these varied experiences shape your perspective on the important intersection of healthcare delivery, business strategy, and policy?
I have had the good fortune of being at the inflection points for exponential growth in many of the key areas you have mentioned. As a result, one develops an informed perspective in identifying these transformative changes much earlier than others.
Throughout your work with SSB Companies, you’ve collaborated with over 100 healthcare organizations across sectors focusing on optimizing healthcare solutions, investment strategies, financial structures, and governmental contracting. What are some of the key trends or opportunities you see emerging in these sectors today?
Key trends and opportunities are divided into interdependent areas: 1) Clinical Success Models that drive to 2) Business Model and can be 3) operationalized in realistic time frame.
You’ve served on public company boards such as Hospira, MedCath, and PhyAmerica, as well as boards like Phoenix Children’s Hospital and The Health Futures Council at ASU. What lessons from those roles do you think have been most valuable?
Serving on multiple high performing public, private and non-profit boards have remarkable similarity. Organizational success is highly dependent on good Governance driving good management which drives organizational valuation/performance.
You’ve also served in advisory roles to The White House Health Project, U.S. Treasury, and HHS/CMS. How has your experience in government policy and regulatory dynamics helped your ability to guide companies navigating today’s healthcare landscape?
Advisory Boards, specifically ones that involve governmental impact, are almost always policy oriented not fiduciary. Policy may or may not work out the way you think it will and almost never ends up with a “cake” that is baked the way you think it is going to turn out.
In your role as Chairman of Artrya USA, you’re leading efforts around AI-enabled cardiovascular diagnostics — including clinical research, regulatory pathways, and reimbursement. How do you see AI transforming clinical care in the near future, and what are some of the biggest opportunities and challenges you’re seeing in bringing AI-based solutions to market?
AI is one of the most transformational healthcare developments of our lifetime. The question is whether “Enterprise AI” vs. “Point Solution AI” is going to have the greatest impact in the near term ( 5 years ) on healthcare. Many people have different perspectives, but I think remarkable “Solution Oriented AI Healthcare” technology will have the greatest impact.
What draws you to healthcare innovation and joining an Advisory Board like Seed Healthcare’s, whose mission is to disrupt healthcare by backing healthcare innovations focused on preventative healthcare and early disease detection?
I serve on very few Advisory Boards like Seed Healthcare, over the years I have advised KKR, Welch Carson, MAVEN, etc. but it’s no secret that truly transformational technology/breakthroughs are always viewed positively by mainstream science that usually has significant investment in legacy products. Cancer, Heart Disease, and Dementia will all have an “Immune Signature” for low grade inflammation that ultimately will manifest in more severe disease later in life. Early detection and treatment through modalities that exist today is my legacy goal and I think Seed Healthcare is directionally the right step.
